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Background: The temporal relationship between arterial stiffness and blood pressure
(BP) may vary depending on age and other clinical and demographic factors. Since both
BP and arterial stiffness are also affected by inflammatory processes, we examined the
temporal arterial stiffness-BP relationship in patients with rheumatoid arthritis (RA) treated
with either methotrexate (MTX), an anti-rheumatic agent shown to reduce cardiovascular
risk in meta-analyses, or other disease-modifying anti-rheumatic drugs (DMARDs).
Methods: Measurements of clinic and 24-h peripheral and central systolic and diastolic
BP (SBP and DBP), and pulse wave velocity (PWV) were assessed in RA patients on
stable treatment with either MTX ± other DMARDs (MTX group, n = 41, age 61 ± 14
years, 73% females) or other DMARDs (non-MTX group, n= 18, age 65± 13 years, 89%
females). Measurements were performed at baseline and after 8 months. The temporal
relationships were examined using cross-lagged path analysis with models that included
age, sex, body mass index, prednisolone, and folic acid use and 28-joint disease activity
score.
Results: There were significant differences in the temporal arterial stiffness-BP
relationships between those in the MTX and DMARD groups. A higher PWV at baseline
caused a significant increase in 6 out of 8 different measures of SBP at 8months amongst
those treated with DMARDs (standardized β, range = 0.54–0.66, p < 0.003 for each)
and 3 out of 8 different measures of DBP (standardized β, range= 0.52–0.61, p < 0.003
for each) but was not associated with either SBP or DBP at 8 months amongst those
treated with MTX. The difference in the effect of baseline PWV on 8-month BP between
the 2 groups was also significant (p < 0.003) for 4 measures including clinic peripheral
SBP (β = 7.0, 95% CI = 2.8–11.1 mmHg per 1m/s higher baseline PWV; p < 0.001).
Woodman et al. Arterial Stiffness, BP and MTX
Conclusions: Higher arterial stiffness preceded increases in BP in subjects with RA
treated with DMARDs, but these effects did not occur amongst those treated with MTX.
The different effects were seen mostly in measures of SBP but were also present in
some measures of DBP. Our findings suggest MTX may confer a protective effect against
stiffness mediated increases in BP in patients with RA.
Keywords: methotrexate, disease-modifying anti-rheumatic drugs, blood pressure, arterial stiffness, pulse wave
velocity, rheumatoid arthritis, cross-lagged path analysis
INTRODUCTION
Arterial stiffness and blood pressure (BP) are two well established
independent risk factors for cardiovascular disease (CVD), yet
both are also closely associated with each other (Mitchell,
2014). The relationship between the two parameters is likely
to be bidirectional based on haemodynamic, vascular biology,
and physiology principles, with both factors potentially capable
of influencing one another. Thus, whilst arterial stiffening
may cause increases in blood pressure due to a reduced
ability to buffer the BP waveform, it is also possible that the
increased damage to arteries from higher BP may lead to
an increase in arterial stiffness (Mitchell, 2014). A stronger
temporal effect of BP on arterial stiffness than vice-versa was
recently observed in middle aged adults without hypertension
followed for a period of 7 years (Chen et al., 2016). This was
however in contrast to other studies, mostly cross-sectional
and in older populations, that have generally found a stronger
effect of arterial stiffness on BP (Najjar et al., 2008). The
strength of each temporal relationship may therefore depend
on the populations studied whereby age and other factors
related to the underlying pathophysiology may determine the
dominating causal effects. One such factor is represented by
chronic systemic inflammation, a common feature in patients
with autoimmune disease states such as rheumatoid arthritis
(RA), a condition notoriously associated with a significant
increase in cardiovascular morbidity and mortality when
compared to the general population (Avina-Zubieta et al.,
2008).
In addition to their known status as CVD risk factors in the
general population, increased BP (Baghdadi et al., 2015) and
increased arterial stiffness (Ikdahl et al., 2016) also increase the
risk of CVD in RA patients. Methotrexate (MTX) is a commonly
used disease-modifying anti-inflammatory drug (DMARD) in
this population and observational studies have shown that MTX
treatment is associated with a lower clinic BP and a reduced
prevalence of hypertension in RA patients (Cuchacovich and
Espinoza, 2009; Mangoni et al., 2017). Furthermore, recent meta-
analyses have shown that the use ofMTX in RA and other chronic
inflammatory states is associated with a significantly lower
risk of cardiovascular events, including myocardial infarction
(Roubille et al., 2015). Since inflammation is also associated
with arterial stiffening and elevated BP (Savoia and Schiffrin,
2006; Jain et al., 2014), use of methotrexate may influence
the causal effects of elevated stiffness on increases in BP
unlike other DMARDs, despite similar anti-inflammatory effects.
However, the predominating temporal relationships between
BP and arterial stiffness has not yet been assessed in the RA
population.
In this medium term follow-up study of 8 months, we
performed repeat assessments of arterial stiffness using pulse
wave velocity (PWV) and both clinic and 24-h ambulatory blood
pressure (peripheral and central) in a cohort of 59 subjects with
a confirmed diagnosis of RA. We then determined the temporal
associations between stiffness and BP in those subjects treated
with methotrexate + DMARDs (n = 41) and in those not using
methotrexate and treated only with DMARDs (n= 18).
METHODS
Study Design
We conducted a repeat cross-sectional study with measurements
of BP and PWV at baseline and at 8 months follow-up. A cross-
lagged panel approach (Selig and Little, 2012) was used for the
analysis to determine the strength of the temporal relationships
between baseline PWV and 8-month BP, and between baseline
BP and 8-month PWV. In total, we recorded 16 measures of BP;
8 × SBP and × DBP, with each including clinic, day-time, night-
time, 24-h, for both peripheral and central measures. Figure 1
shows an example of the cross-lagged causal pathways for PWV
and clinic peripheral SBP. The arrows indicate causal directions
e.g., clinic peripheral SBP at baseline affecting clinic peripheral
SBP and PWV at 8-month follow-up. Our primary interest was
to determine the strength of the relationships between baseline
PWV and follow-up BP (β1) and the association between baseline
BP and follow-up PWV (β2).
Patient Recruitment and Ethical Approval
We studied a consecutive series of patients with stable RA,
aged ≥18 years, recruited from the outpatient clinics of the
Rheumatology Department at Flinders Medical Centre and
the Repatriation General Hospital, in the Southern Health
Local Heath Network, Adelaide, Australia. RA was diagnosed
according to the 1987 American College of Rheumatology or
the 2010 American College of Rheumatology/European League
Against Rheumatism criteria (Aletaha et al., 2010). Study
participants were classified as currently treated with MTX for
at least 8 weeks (MTX group), or not taking MTX for at least
1 year or being MTX-naïve and treated with other synthetic
and/or biologic DMARDs (non-MTX group). Exclusion criteria
were atrial fibrillation, active cancer or current treatment with
anti-cancer drugs, heart failure, and cognitive impairment.
The study (registered in the Australian New Zealand
Clinical Trials Registry with the registration number
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FIGURE 1 | β1, cross-lagged path coefficient from baseline PWV to follow-up clinic peripheral systolic blood pressure (SBP); β2, cross-lagged path coefficient from
baseline clinic peripheral SBP to follow-up PWV. Baseline measures of age, gender, BMI, DAS, serum CRP, and use of folic acid and prednisolone are included as
covariates. Arrows indicate hypothesized causal directions and when significant in the cross-lagged path analysis this provides an indication of causality.
ACTRN12616001366448) was approved by the Southern
Adelaide Clinical Human Research Ethics Committee (Ethics
Approval Number: 76.14). Each participant gave written consent
before entering the study in accordance with the Declaration of
Helsinki.
Clinic Peripheral and Central Blood
Pressure
Clinic peripheral systolic (SBP) and diastolic (DBP) BP were
measured in the morning, in a quite environment at room
temperature, using the clinically validated automatic BP monitor
(model UA-767PC; AND Medical, Sydney, Australia) according
to current guidelines (Palatini et al., 1998; Baghdadi et al.,
2015; Gabb et al., 2016). The average of the last two sitting
BP measurements was calculated and used in analyses. Clinic
central SBP and DBP was measured non-invasively using Pulse
Wave Analysis (PWA, SphygmoCor version 7.1, AtCor Medical,
Sydney, Australia; O’Rourke et al., 2001).
24-h Peripheral and Central Blood
Pressure and PWV
Twenty-four hour, daytime (between 08:00 a.m. and 12:00 a.m.),
and night-time (between 12:00 a.m. and 08:00 a.m.; Fagard
et al., 1996) peripheral and central BP and PWV were measured
using a validated ambulatory oscillometric BP monitor (Mobil-
O-Graph PWA monitor, IEM, Stolberg, Germany; Jones et al.,
2000;Westhoff et al., 2005; Franssen and Imholz, 2010;Wei et al.,
2010). The central BP measurement, similar to that measured
using the SphygmoCor device (Weiss et al., 2012), is based on
the ARCSolver method, which determines aortic BP and PWV
using the oscillometric BP technique (Wassertheurer et al., 2010;
Weber et al., 2011).
Clinical and Demographic Characteristics
The following data were collected from patient interviews,
medical questionnaires, clinical notes, and hospital
administrative databases: age, gender, medical, and medication
history, Stanford health assessment questionnaire (HAQ)
(Pincus et al., 1983), pain visual analog scale (McCormack et al.,
1988), global health score (Anderson et al., 2012), weight, height,
body mass index (BMI), and the 28-joint disease activity score
(DAS28) (Prevoo et al., 1995).
C-Reactive Protein
High-sensitivity C-reactive protein (CRP) was measured
in serum by latex-enhanced immunoturbidimetry on an
automated Modular PPE Analyzer (Roche Diagnostics; Pepys
and Hirschfield, 2003).
Statistical Analysis
Each analysis was performed in Stata version 14.2 (StataCorp,
Texas, USA) using commands for structural equation modeling
(SEM) with maximum-likelihood estimation. For each of the
16 different BP outcome variables we fitted a separate SEM
model with MTX treatment status as a separate strata (grouping)
variable. The endogenous (dependent) variables in each model
were baseline and follow-up BP, and baseline and follow-up
PWV. Exogenous (independent) variables in each model were
age, gender, BMI, DAS28, serum CRP, and use of folic acid
and prednisolone which were used as predictors of the baseline
measures of BP and PWV. Measurement errors between BP
and PWV were also allowed to co-vary at each time-point
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TABLE 1 | Baseline clinical and demographic characteristics of the MTX and the non-MTX groups.
All subjects (n = 59) Non-MTX group (n = 18) MTX group (n = 41) P-valuea
Age (years) 62 ± 13 65 ± 13 61 ± 14 0.34
Females (%) 78.0 88.9 73.2 0.18
Body Mass Index (Kg/m2) 27.8 ± 6.2 28.6 ± 6.3 27.5 ± 6.2 0.55
Current smoking (%) 13.6 5.6 17.1 0.23
Hypertension (%) 35.6 38.9 34.2 0.73
Diabetes (%) 10.2 22.2 4.9 0.06
Dyslipidaemia (%) 30.5 38.9 26.8 0.75
Previous cardiovascular event (%) 8.5 22.2 2.4 0.03
Chronic kidney disease (%) 3.4 5.6 2.4 0.52
Liver disease (%) 3.4 5.6 2.4 0.52
Depression (%) 22.0 38.9 14.6 0.04
RA duration (years) 11 [4, 24] 15 [8, 27] 9 [3, 23] 0.21
MTX dose (mg/week) 14.3 ± 5.2 14.3 ± 5.2 – –
DAS28 score 3.0 ± 1.2 3.7 ± 1.0 2.6 ± 1.1 <0.001
C-reactive protein (mg/L) 1.90 [0.57, 6.0] 1.95 [0.74, 4.1] 1.90 [0.57, 6.7] 0.76
Stanford HAQ score 0.5 [0.0, 1.5] 1.065 [0.38, 1.75] 0.25 [0.00, 1.13] 0.06
Pain visual analog score 0.76 [0.20, 1.34] 0.90 [0.40, 1.52] 0.70 [0.08, 1.24] 0.13
Global health score 0.58 [0.08, 1.30] 0.10 [0.38, 1.40] 0.30 [0.04, 0.96] 0.03
Hydroxychloroquine (%) 25.4 22.2 26.8 0.49
Leflunomide (%) 5.1 0.0 7.3 0.55
Sulfasalazine (%) 15.3 22.2 12.2 0.43
Abatacept (%) 3.4 5.6 2.4 0.52
Rituximab (%) 0.0 0.0 0.0 1.00
Tocilizumab (%) 8.5 22.2 2.4 0.03
Adalimumab (%) 6.8 5.6 7.3 0.64
Etanercept (%) 23.7 33.3 19.5 0.32
Certolizumab pegol (%) 1.7 2.4 0.0 1.00
Golimumab (%) 5.1 0.0 7.3 0.55
Prednisolone (%) 33.9 33.3 34.1 0.95
Prednisolone daily dose (mg) 5 [4.75, 7.50] 5.00 [4.0, 5.0] [5.00 4.5, 10.0] 0.89
Ibuprofen (%) 6.8 0.0 9.8 0.30
Aspirin* (%) 18.6 22.2 17.1 0.72
Antihypertensive drugs (%) 27.1 27.8 26.8 1.00
Folic acid (%) 54.2 5.6 75.6 <0.001
Fish oil (%) 37.3 27.8 41.5 0.39
MTX, methotrexate; RA, rheumatoid arthritis; DAS, disease activity score 28; HAQ, health assessment questionnaire. *Daily dose 100mg in all patients.
aUsing t-test, χ2-test or Fishers Exact as appropriate. Figures are Mean ± SD, median[25th percentile, 75th percentile], or n(%).
(Figure 1). The specific coefficients of interest were the effect of
baseline PWV on follow-up BP (β1) and the effect of baseline
BP on follow-up PWV (β2). Stratifying by MTX treatment status
allowed separate coefficient estimates for each group of subjects
and also calculation of the difference (and confidence intervals)
for each coefficient between the 2 groups. We also performed
a formal Wald test of group invariance in each coefficient to
formally test whether the 2 estimates for each coefficient were the
same for both groups. Model fit was determined using standard
SEM measures: the chi-square (χ2) test of model fit vs. saturated
fit for which non-significant values (p> 0.05) indicate acceptable
fit, the comparative fit index (CFI) for which values >0.90 reflect
acceptable model fit, and values >0.95 reflect excellent model
fit, and the standardized root-mean-square residual (SRMSR) for
which values of 0.05 or less reflect excellent model fit, while a
value of <0.08 reflects a good fit. Given the 16 different measures
of BP that were assessed, a Bonferroni correction was applied to
the results and coefficients were only considered significant for p




Table 1 describes the baseline clinical and demographic
characteristics of the patients in the MTX and the non-MTX
groups. The mean (±SD) age of the population was 62 ± 13
and 78% were females. There were no differences between the
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non-MTX group of subjects and those taking MTX in terms of
other medication use, chronic diseases and disease scores except
for a significant difference for the presence of depression (38.9
vs. 14.6%, respectively, p = 0.04), the use of folic acid (5.6 vs.
75.6%; p < 0.001), the DAS28 (3.7± 1.0 vs. 2.6± 1.1, p < 0.001),
and the Global Health score [median (IQR) 0.1 (0.38, 1.40) vs.
0.3 (0.04, 0.96); p= 0.03].
Table 2 describes the correlations, means and standard
deviations for 24 h PWV, clinic peripheral SBP and 24 h
peripheral SBP at the baseline and 8-month assessments (n =
59). Across the 2 time points, there was a slight increase in both
clinic and ambulatory BP but there was no significant change in
PWV. Amongst the 16 different measures of BP, pairwise Pearson
correlations between measures of baseline SBP and follow-up
PWV were moderate (r = 0.31–0.54), correlations between
baseline DBP and follow-up PWV were weak (r = 0.06–0.20),
correlations between baseline PWV and follow-up SBP were
moderate (r = 0.40–0.55), correlations between baseline PWV
and follow-up DBP were weak to moderate (r = −0.02 to 0.44),
whilst correlations between baseline and follow-up measures of
PWV were high (r = 0.91).
Effect of PWV on BP (β1 Path Coefficients)
Figure 2 shows the standardized estimates with 99.7% CI’s for
β1 by DMARD treatment regime. For subjects in the non-MTX
group, out of the 8 measures of SBP, all except 24 h peripheral
SBP and night-time peripheral SBP showed a significant effect of
baseline PWV on follow-up BP (standardized β, range = 0.54–
0.66, p < 0.003 for each). Out of the 8 measures of DBP, 3
showed a significant effect of baseline PWV on follow-up BP
(standardized β, range= 0.54–0.66, p< 0.003 for each) including
night-time peripheral, 24-h central and night-time central DBP.
There were no significant effects of baseline PWV onmeasures of
either SBP or DBP amongst subjects using MTX.
Effect of BP on PWV (β2 Path Coefficients)
Figure 3 shows the standardized estimates with 99.7% CI’s for β2
by type of DMARD. For both those subjects in the non-MTX
group and those in the MTX group, there were no significant
effects of baseline SBP or baseline DBP, on follow-up PWV.
Difference in Path Coefficients between
Groups
Figure 4 shows the difference in the estimated effects of
baseline PWV on increases in BP at 8 months (β1) for the
different treatments (DMARDs vs. MTX). There was a significant
difference between groups in the estimated effects for clinic
peripheral SBP, clinic central SBP, 24 h central SBP and night
central SBP (p < 0.003 for each). The largest difference in the
effect occurred for clinic peripheral SBP (β = 7.0, 95% CI = 2.8–
11.1 mmHg per 1m/s higher baseline PWV; p < 0.001). There
were no significant differences between groups in the effects of
baseline PWV on any of the measures of follow-up DBP. There
were also no significant differences between groups in β2 (effect of
baseline BP on follow-up PWV) for any of the 16 measures of BP.
The Wald test for group invariance in the estimated coefficients
between the 2 groups showed a significant difference in the β1
TABLE 2 | Correlation matrix and descriptive statistics for PWV and clinic and









Clinic SBP 0M 1.00
24 h PWV 0M 0.51 1.00
Clinic SBP 8M 0.66 0.51 1.00
24 h PWV 8M 0.54 0.91 0.55 1.00
N 59 59 59 59
Mean 126.1 9.10 127.7 9.08









Clinic SBP 0M 1.00
24 h PWV 0M 0.53 1.00
Clinic SBP 8M 0.56 0.40 1.00
24 h PWV 8M 0.43 0.91 0.44 1.00
N 59 59 59 59
Mean 126.5 9.10 107.9 9.08
SD 12.7 2.01 15.41 2.18
SD, standard deviation.
coefficient for clinic peripheral SBP (p = 0.0004), clinic central
SBP (p = 0.006), day-time peripheral SBP (p = 0.014), 24 h
central SBP (p = 0.005), day-time central SBP (p = 0.045), and
night-time central SBP (p = 0.013). There was also a significant
difference in the β2 coefficient for clinic peripheral DBP (p =
0.043) and clinic central DBP (p= 0.046; Figures 3, 4).
Model Fit Statistics
Table 3 describes the various indices of model fit for each of the
16 measures of BP. Overall, the indices indicated excellent model
fit with the mean CFI = 0.956 and the mean SRMSR = 0.046.
The mean χ2 value for the fitted model vs. the saturated model
was χ2 = 44.0 (28 df) (p= 0.028) indicating acceptable fit.
Changes in Heart Rate and CRP
Table 4 displays the changes between baseline and follow-up
in average 24-h heart rate and log-transformed CRP for each
of the 2 groups, as well as the associated differences in these
changes between groups. There were no significant differences
between baseline and follow-up for each group, and no significant
difference in the change between groups.
DISCUSSION
In this repeat cross-sectional study of patients with stable RA,
we examined the strength of the temporal relationships between
arterial stiffness (PWV) and follow-up BP and between baseline
BP and follow-up PWV. We observed evidence for a causal
effect of arterial stiffness on increased SBP in subjects not treated
with MTX. The effects were seen for both central and peripheral
and for clinic and ambulatory SBP. The effects were similar
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FIGURE 2 | Standardized coefficients (and 99.7% confidence intervals) describing the correlation between baseline PWV and BP at follow-up BP (β1). The
standardized β1 can be interpreted as the number of SD increases in BP at 8 months for each one SD increase in PWV at baseline. For example, the standardized β1
coefficient for baseline PWV on clinic peripheral SBP for the other DMARDS group is β1 = 0.66 (99.7% CI = 0.37–0.96).
FIGURE 3 | Standardized coefficients (and 99.7% confidence intervals) describing the correlation between baseline BP at follow-up PWV (β2). The standardized β2
can be interpreted as the number of SD increases in PWV at 8 months for each one SD increase in BP at baseline. For example, the standardized β2 coefficient for
baseline BP on clinic peripheral PWV for the other DMARDS group is β2 = 0.02 (99.7% CI = −0.09–0.14).
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FIGURE 4 | Differences in the effects of baseline PWV on follow-up BP between DMARDS group and MTX group. The estimated effects (β) are the differences in
increased blood pressure (in mmHg) at 8 months for a 1m/s higher baseline PWV for DMARDS vs. MTX.
TABLE 3 | Indices of model fit for each of the 16 blood pressure models.
Blood pressure variable χ2 test (28 df)a p-value CFIb SRMSRv
Clinic peripheral SBP 44.8 0.023 0.95 0.05
Clinic central SBP 38.9 0.082 0.97 0.05
24 h peripheral SBP 36.8 0.122 0.98 0.03
Day peripheral SBP 36.1 0.141 0.98 0.04
Night peripheral SBP 47.4 0.012 0.95 0.04
24 h central SBP 35.8 0.147 0.98 0.04
Day central SBP 34.3 0.190 0.98 0.04
Night central SBP 47.4 0.013 0.95 0.05
Clinic peripheral DBP 32.6 0.253 0.99 0.05
Clinic central DBP 37.1 0.116 0.97 0.06
24 h peripheral DBP 49.6 0.007 0.93 0.05
Day peripheral DBP 60.7 <0.001 0.91 0.06
Night peripheral DBP 51.1 0.005 0.93 0.04
24 h central DBP 55.8 0.001 0.93 0.05
Day central DBP 47.2 0.013 0.95 0.05
Night central DBP 47.9 0.011 0.94 0.04
aChi-squared test of fitted model vs. saturated fit with 28 degrees of freedom;
bCFI, Comparative fit index;
cSRMSR, Standardized Root Mean Square Residual.
during the day and night and we also observed the same effect
of PWV on night-time and 24 h central DBP amongst subjects
not taking MTX. By contrast, none of the causal effects of
increased stiffness on BP were observed amongst subjects treated
with MTX medication. Since the differences in causal effects
were predominantly related to systolic blood pressure, rather
than diastolic pressure, this suggests the possible involvement of
effects on stroke volume. Since we did not measure stroke volume
directly, further studies are required to determine whether this
parameter might explain, at least in part, the observed between-
group differences.
Since inflammation is believed to have a primary influence
in the pathophysiology of increased arterial stiffness (Jain et al.,
2014), studying a population known to have high underlying
levels of inflammation, and associated cardiovascular risk,
provides a valuable opportunity to examine the extent to which
inflammation and specific DMARDs may influence the stiffness-
BP relationship. The 2 groups of subjects within our own
study had similar values of PWV at baseline, which were
in line with values normally seen for their age. Our results
therefore suggest that arterial stiffness related increases in BP
were prevented in those using MTX. If this finding were also
to be observed in individuals without RA, it would support the
idea that the effects of increased arterial stiffness may partly be
due to underlying inflammation, and that MTX acts to disrupt
these specific pathways more effectively than other DMARDs.
Furthermore, MTX appears to exert additional vasculoprotective
effects independent of reduced inflammation, through the
accumulation of adenosine, a vasodilator, BP lowering, and
stimulating nitric-oxide (NO) synthesis agent, and stimulation of
5′ AMP-activated protein kinase (AMPK) (Costa and Biaggioni,
1998; Tian and Cronstein, 2007; Schneider et al., 2015; Thornton
et al., 2016). In this study we observed non-significant reductions
in CRP, a measure of systemic inflammation, of ∼37% in each
group, suggesting that systemic inflammation was not a major
explanatory factor of the observed causal effects.
Frontiers in Physiology | www.frontiersin.org 7 August 2017 | Volume 8 | Article 593
Woodman et al. Arterial Stiffness, BP and MTX
TABLE 4 | Twenty-four hour heart rate and CRP values at baseline and follow-up for each group and estimated changes.
24-h heart rate Change MTX vs. Non-MTX (p-value)b
0 months 8 months Changea
Non-MTX (n = 18) 68.9 ± 10.7 69.1 ± 8.6 0.2 ± 1.7 (p = 0.90)
MTX (n = 41) 71.2 ± 9.4 70.2 ± 9.6 −1.1 ± 1.1 (p = 0.35) −1.30 ± 2.07 (0.53)
Log CRP
0 months 8 months Changea
Non-MTX (n =1 8) 0.57 ± 1.31 0.40 ± 1.31 −0.21 ± 0.36 (p = 0.56)
MTX (n = 41) 0.79 ± 1.67 0.49 ± 1.61 −0.30 ± 0.23 (p = 0.19) −0.09 ± 0.43 (p = 0.83)
aAdjusted marginal means using mixed effects linear regression model.
bFrom MTX × visit interaction term.
Our results may not be generalizable to all individuals
with RA, particularly younger patients. Our cohort was typical
of the RA population and consisted of mostly middle-aged
to older patients. Recently, the Bogalusa study, a 7 year
longitudinal cohort study in a younger population of adults,
used similar methods to ours to examine the dominant
temporal relationship between arterial stiffness and BP. In
this younger cohort they reported that elevated BP precedes
increased arterial stiffness rather than vice-versa (Chen et al.,
2016) and concluded that amongst younger adults the arterial
wall may not yet be stiff enough to significantly influence
BP.
Our study had a number of strengths. Firstly we used cross-
lagged path analysis, a specific form of path analysis that
simultaneously examines reciprocal, longitudinal relationships
among a set of inter-correlated variables and allows better
determination of causal relationships (Selig and Little, 2012).
Overall, our models provided excellent levels of fit indicating that
the proposed causal pathways were feasible for the given data.
In addition we used a wide variety of BP measures including
24 h BP monitoring with repeat measurements every 20 min
during the day and every 30 min during the night. This reduces
measurement error and increases statistical power. We also
collected clinical data on a large number of potential confounders
and were able to demonstrate similarity between groups except
for a few variables including DAS28 and use of folic acid that were
adjusted for in our analysis.
There are several limitations to our study. The duration
of follow-up in our study was relatively short with a mean
of 8 months. Most of the evidence from other studies have
been derived from cohorts with between 4 and 8 years
average follow-up in which larger effects are likely to occur
(Chen et al., 2016). However, the strength of the associations
observed in these studies and our own study were similar.
In addition, our sample size was relatively small and so we
may have been underpowered to detect some of the smaller
effects that were observed. Although, characteristic of a RA
population, the study population was also fairly heterogeneous
with some subjects receiving BP medications as well as different
anti-inflammatory medications for the treatment of their RA.
Although, we adjusted for the use of prednisolone, a more
homogeneously treated population would allow us to better
explore the associations without the risk of selection bias. Finally,
although we tried to reduce the possibility of confounding
and also used a structural equation modeling approach to
better identify the most likely direction of causality, the results
may still be influenced by residual confounding and reverse
causality since not all subjects were free of cardiovascular
disease at baseline. A fully randomized controlled trial in
a disease free non-hypertensive population is required to
determine both the true causal effects of PWV on BP and also
whether MTX use can inhibit the damaging effects of increased
stiffness.
In summary we have demonstrated that although
elevated arterial stiffening preceded increases in BP in
subjects with RA, these effects did not occur amongst
those patients using MTX medication. The beneficial
effects were seen mostly in SBP but were also apparent
to some degree with DBP, particularly with regards to
the more accurate assessment of 24-h blood pressures.
These findings suggest MTX may confer a protective
effect against stiffness mediated increases in BP in patients
with RA.
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